Search

Your search keyword '"Tran, Phuoc T"' showing total 876 results
Start Over Author "Tran, Phuoc T"
876 results on '"Tran, Phuoc T"'

201. Impact of initial treatment selection on clinical outcomes after biochemical failure in radiorecurrent high-risk prostate cancer.

Author

Levin-Epstein, Rebecca, primary, Romero, Tahmineh, additional, Wong, Jessica Karen, additional, Cook, Kiri, additional, Dess, Robert Timothy, additional, Spratt, Daniel Eidelberg, additional, Moran, Brian Joseph, additional, Merrick, Gregory Stephen, additional, Tran, Phuoc T., additional, Demanes, David Jeffrey, additional, Stish, Brad J., additional, Krauss, Daniel J., additional, Wedde, Trude Baastad, additional, Lilleby, Wolfgang, additional, Stock, Richard, additional, Tward, Jonathan David, additional, Steinberg, Michael L., additional, Horwitz, Eric M., additional, Tendulkar, Rahul D., additional, and Kishan, Amar Upadhyaya, additional

Published
2020
Full Text
View/download PDF

202. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Author

Tran, Phuoc T., primary, Phillips, Ryan, additional, Shi, William, additional, Lim, Su Jin, additional, Antonarakis, Emmanuel S., additional, Rowe, Steven P., additional, Ross, Ashley, additional, Gorin, Michael A., additional, Deville, Curtiland, additional, Greco, Stephen C., additional, Paller, Channing Judith, additional, DeWeese, Theodore L., additional, Song, Daniel Y., additional, Wang, Hao, additional, Carducci, Michael Anthony, additional, Pienta, Kenneth J., additional, Pomper, Martin, additional, Dicker, Adam P., additional, Eisenberger, Mario A., additional, and Diehn, Maximilian, additional

Published
2020
Full Text
View/download PDF

203. Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer.

Author

Parikh, Neil Rohit, primary, Chang, Eric M., additional, Nickols, Nicholas George, additional, Rettig, Matthew, additional, Raldow, Ann C., additional, Steinberg, Michael L., additional, Koontz, Bridget F., additional, Vapiwala, Neha, additional, Deville, Curtiland, additional, Feng, Felix Y, additional, Spratt, Daniel Eidelberg, additional, Reiter, Robert Evan, additional, Phillips, Ryan, additional, Tran, Phuoc T., additional, and Kishan, Amar Upadhyaya, additional

Published
2020
Full Text
View/download PDF

206. MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity

Author

Dhanasekaran, Renumathy, primary, Baylot, Virginie, additional, Kim, Minsoon, additional, Kuruvilla, Sibu, additional, Bellovin, David I, additional, Adeniji, Nia, additional, Rajan KD, Anand, additional, Lai, Ian, additional, Gabay, Meital, additional, Tong, Ling, additional, Krishnan, Maya, additional, Park, Jangho, additional, Hu, Theodore, additional, Barbhuiya, Mustafa A, additional, Gentles, Andrew J, additional, Kannan, Kasthuri, additional, Tran, Phuoc T, additional, and Felsher, Dean W, additional

Published
2020
Full Text
View/download PDF

207. Author response: MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity

Author

Dhanasekaran, Renumathy, primary, Baylot, Virginie, additional, Kim, Minsoon, additional, Kuruvilla, Sibu, additional, Bellovin, David I, additional, Adeniji, Nia, additional, Rajan KD, Anand, additional, Lai, Ian, additional, Gabay, Meital, additional, Tong, Ling, additional, Krishnan, Maya, additional, Park, Jangho, additional, Hu, Theodore, additional, Barbhuiya, Mustafa A, additional, Gentles, Andrew J, additional, Kannan, Kasthuri, additional, Tran, Phuoc T, additional, and Felsher, Dean W, additional

Published
2019
Full Text
View/download PDF

208. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer

Author

Ross, Ashley E., primary, Hurley, Paula J., additional, Tran, Phuoc T., additional, Rowe, Steven P., additional, Benzon, Benjamin, additional, Neal, Tanya O’, additional, Chapman, Carolyn, additional, Harb, Rana, additional, Milman, Yelena, additional, Trock, Bruce J., additional, Drake, Charles G., additional, and Antonarakis, Emmanuel S., additional

Published
2019
Full Text
View/download PDF

214. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition

Author

Ferguson, Lynnette R., Chen, Helen, Collins, Andrew R., Connell, Marisa, Damia, Giovanna, Dasgupta, Santanu, Malhotra, Meenakshi, Meeker, Alan K., Amedei, Amedeo, Amin, Amr, Ashraf, S. Salman, Aquilano, Katia, Azmi, Asfar S., Bhakta, Dipita, Bilsland, Alan, Boosani, Chandra S., Chen, Sophie, Ciriolo, Maria Rosa, Fujii, Hiromasa, Guha, Gunjan, Halicka, Dorota, Helferich, William G., Keith, W. Nicol, Mohammed, Sulma I., Niccolai, Elena, Yang, Xujuan, Honoki, Kanya, Parslow, Virginia R., Prakash, Satya, Rezazadeh, Sarallah, Shackelford, Rodney E., Sidransky, David, Tran, Phuoc T., Yang, Eddy S., and Maxwell, Christopher A.

Subjects
Centrosome, Genomic instability, Cancer Research, DNA Repair, Cancer therapy, Review, Prognosis, Diet, Cancer prevention, Neoplasms, Humans, DNA damage, Nutraceutical, Settore BIO/10, Telomerase
Abstract

Genomic instability can initiate cancer, augment progression, and influence the overall prognosis of the affected patient. Genomic instability arises from many different pathways, such as telomere damage, centrosome amplification, epigenetic modifications, and DNA damage from endogenous and exogenous sources, and can be perpetuating, or limiting, through the induction of mutations or aneuploidy, both enabling and catastrophic. Many cancer treatments induce DNA damage to impair cell division on a global scale but it is accepted that personalized treatments, those that are tailored to the particular patient and type of cancer, must also be developed. In this review, we detail the mechanisms from which genomic instability arises and can lead to cancer, as well as treatments and measures that prevent genomic instability or take advantage of the cellular defects caused by genomic instability. In particular, we identify and discuss five priority targets against genomic instability: (1) prevention of DNA damage; (2) enhancement of DNA repair; (3) targeting deficient DNA repair; (4) impairing centrosome clustering; and, (5) inhibition of telomerase activity. Moreover, we highlight vitamin D and B, selenium, carotenoids, PARP inhibitors, resveratrol, and isothiocyanates as priority approaches against genomic instability. The prioritized target sites and approaches were cross validated to identify potential synergistic effects on a number of important areas of cancer biology.

Published
2015
Full Text
View/download PDF

215. Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease

Author

Tseng Diane, Rachakonda Leelanand P, Su Zheng, Advani Ranjana, Horning Sandra, Hoppe Richard T, Quon Andrew, Graves Edward E, Loo Billy W, and Tran Phuoc T

Subjects
Hodgkin's disease, PET, metabolic tumor volume, quantitative PET parameters, survival, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Purpose We hypothesized that quantitative PET parameters may have predictive value beyond that of traditional clinical factors such as the International Prognostic Score (IPS) among Hodgkin's disease (HD) patients. Methods Thirty HD patients treated at presentation or relapse had staging and interim-treatment PET-CT scans. The majority of patients (53%) had stage III-IV disease and 67% had IPS ≥ 2. Interim-treatment scans were performed at a median of 55 days from the staging PET-CT. Chemotherapy regimens used: Stanford V (67%), ABVD (17%), VAMP (10%), or BEACOPP (7%). Hypermetabolic tumor regions were segmented semiautomatically and the metabolic tumor volume (MTV), mean standardized uptake value (SUVmean), maximum SUV (SUVmax) and integrated SUV (iSUV) were recorded. We analyzed whether IPS, absolute value PET parameters or the calculated ratio of interim- to pre-treatment PET parameters were associated with progression free survival (PFS) or overall survival (OS). Results Median follow-up of the study group was 50 months. Six of the 30 patients progressed clinically. Absolute value PET parameters from pre-treatment scans were not significant. Absolute value SUVmax from interim-treatment scans was associated with OS as determined by univariate analysis (p < 0.01). All four calculated PET parameters (interim/pre-treatment values) were associated with OS: MTVint/pre (p < 0.01), SUVmeanint/pre (p < 0.05), SUVmaxint/pre (p = 0.01), and iSUVint/pre (p < 0.01). Absolute value SUVmax from interim-treatment scans was associated with PFS (p = 0.01). Three calculated PET parameters (int/pre-treatment values) were associated with PFS: MTVint/pre (p = 0.01), SUVmaxint/pre (p = 0.02) and iSUVint/pre (p = 0.01). IPS was associated with PFS (p < 0.05) and OS (p < 0.01). Conclusions Calculated PET metrics may provide predictive information beyond that of traditional clinical factors and may identify patients at high risk of treatment failure early for treatment intensification.

Published
2012
Full Text
View/download PDF

218. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects

Author

Isaacsson Velho, Pedro, primary, Qazi, Fahad, additional, Hassan, Sayeedul, additional, Carducci, Michael A., additional, Denmeade, Samuel R., additional, Markowski, Mark C., additional, Thorek, Daniel L., additional, DeWeese, Theodore L., additional, Song, Daniel Y., additional, Tran, Phuoc T., additional, Eisenberger, Mario A., additional, and Antonarakis, Emmanuel S., additional

Published
2019
Full Text
View/download PDF

221. Genomic biomarkers to predict outcome in Gleason Score 9-10 disease.

Author

Kishan, Amar Upadhyaya, primary, Romero, Tahmineh, additional, Elashoff, David, additional, Grogan, Tristan, additional, Rettig, Matthew, additional, Reiter, Robert Evan, additional, Tran, Phuoc T., additional, Nguyen, Paul L., additional, Nickols, Nicholas George, additional, Davicioni, Elai, additional, Spratt, Daniel Eidelberg, additional, Feng, Felix Y, additional, and Weidhaas, Joanne B., additional

Published
2019
Full Text
View/download PDF

222. Clinical Development of Novel Drug–Radiotherapy Combinations

Author

Ahmad, Saif S., primary, Crittenden, Marka R., additional, Tran, Phuoc T., additional, Kluetz, Paul G., additional, Blumenthal, Gideon M., additional, Bulbeck, Helen, additional, Baird, Richard D., additional, Williams, Kaye J., additional, Illidge, Tim, additional, Hahn, Stephen M., additional, Lawrence, Theodore S., additional, Spears, Patricia A., additional, Walker, Amanda J., additional, and Sharma, Ricky A., additional

Published
2019
Full Text
View/download PDF

224. Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series

Author

Tran Phuoc T, Zeng Jing, See Alfred P, and Lim Michael

Subjects
Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background There is little data on the safety of combining radiation therapy and human immunodeficiency virus (HIV) protease inhibitors to treat cancers in HIV-positive patients. We describe acute toxicities observed in a series of HIV-positive patients receiving modern radiation treatments, and compare patients receiving HIV protease inhibitors (PI) with patients not receiving HIV PIs. Methods By reviewing the clinical records beginning January 1, 2009 from the radiation oncology department, we identified 29 HIV-positive patients who received radiation therapy to 34 body sites. Baseline information, treatment regimen, and toxicities were documented by review of medical records: patient age, histology and source of the primary tumor, HIV medication regimen, pre-radiation CD4 count, systemic chemotherapy, radiation therapy dose and fractionation, irradiated body region, toxicities, and duration of follow-up. Patients were grouped according to whether they received concurrent HIV PIs and compared using Pearson's chi-square test. Results At baseline, the patients in the two groups were similar with the exception of HIV medication regimens, CD4 count and presence of AIDS-defining malignancy. Patients taking concurrent PIs were more likely to be taking other HIV medications (p = 0.001) and have CD4 count >500 (p = 0.006). Patients taking PIs were borderline less likely to have an AIDS-defining malignancy (p = 0.06). After radiation treatment, 100 acute toxicities were observed and were equally common in both groups (64 [median 3 per patient, IQR 1-7] with PIs; 36 [median 3 per patient, IQR 2-3] without PIs). The observed toxicities were also equally severe in the two groups (Grades I, II, III respectively: 30, 30, 4 with PIs; 23, 13, 0 without PIs: p = 0.38). There were two cases that were stopped early, one in each group; these were not attributable to toxicity. Conclusions In this study of recent radiotherapy in HIV-positive patients taking second generation PIs, no difference in toxicities was observed in patients taking PIs compared to patients not taking PIs during radiation therapy. This suggests that it is safe to use unmodified doses of PIs and radiation therapy in HIV cancer patients, and that it is feasible to use PIs as a radiosensitizer in cancer therapy, as has been suggested by pre-clinical results.

Published
2011
Full Text
View/download PDF

226. Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma

Author

Kapp Daniel S, Koong Albert C, Chang Daniel T, Horoschak Melissa, Tseng Diane, Bachireddy Pavan, and Tran Phuoc T

Subjects
Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Purpose To analyze the outcomes of patients from a single institution treated with surgery and orthovoltage intraoperative radiotherapy (IORT) for pancreatic adenocarcinoma. Methods We retrospectively reviewed 23 consecutive patients from 1990-2001 treated with IORT to 23 discrete sites with median and mean follow up of 6.5 and 21 months, respectively. Most tumors were located in the head of the pancreas (83%) and sites irradiated included: tumor bed (57%), vessels (26%), both the tumor bed/vessels (13%) and other (4%). The majority of patients (83%) had IORT at the time of their definitive surgery. Three patients had preoperative chemoradiation (13%). Orthovoltage X-rays (200-250 kVp) were employed via individually sized and beveled cone applicators. Additional mean clinical characteristics include: age 64 (range 41-81); tumor size 4 cm (range 1.4-11); and IORT dose 1106 cGy (range 600-1500). Post-operative external beam radiation (EBRT) or chemotherapy was given to 65% and 76% of the assessable patients, respectively. Outcomes measured were infield control (IFC), loco-regional control (LRC), distant metastasis free survival (DMFS), overall survival (OS) and treatment-related complications. Results Kaplan-Meier (KM) 2-year IFC, LRC, DMFS and OS probabilities for the whole group were 83%, 61%, 26%, and 27%, respectively. Our cohort had three grade 3-5 complications associated with treatment (surgery and IORT). Conclusions Orthovoltage IORT following tumor reductive surgery is reasonably well tolerated and seems to confer in-field control in carefully selected patients. However, distant metastases remain the major problem for patients with pancreatic adenocarcinoma.

Published
2010
Full Text
View/download PDF

228. Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries.

Author

De Bruycker, Aurélie, Tran, Phuoc T., Achtman, Ariel H., Ost, Piet, GAP6 consortium, Boutros, Paul C., Buzza, Mark, Corcoran, Niall M., Dal Pra, Alan, Emmenegger, Urban, Fraser, Michael, Hovens, Chris M., Koontz, Bridget F., Lapointe, Jacques, and Vela, Ian

Subjects
*CLINICAL trial registries, *PROSTATE cancer
Abstract

Purpose: Thanks to the introduction of more sensitive/specific imaging and minimally invasive treatment techniques, the oligometastatic state in prostate cancer (PCa) has attracted the interest of the uro-oncological community. We aim to identify and analyze trials across five registries to gain insights into the directions this field is moving. Methods: A systematic review of trials on oligometastatic PCa registered on ClinicalTrials.gov, ANZCTR, ISRCTN, Netherlands and UMIN Clinical Trials Registries was performed using the following keywords: 'prostate cancer' and 'oligo'. Data were extracted from ongoing/completed trials, with an unreported primary endpoint in a peer-reviewed journal, as of May until August, 2018. Results: We identified 41 trials on oligometastatic PCa. Twenty-four trials are conducted in North America and 14 in Europe. Up to 70% are phase I or II trials and < 10% (n = 4) are in phase III. Less than 50% (n = 17) are randomized controlled trials. Oligometastases are PET detected in 25 trials. Studies on synchronous oligometastatic (n = 12; 29%) or oligorecurrent (n = 14; 34%) PCa are equally represented, the remainder focus on mixed states (n = 15; 37%). The majority (n = 39; 95%) of trials investigate local treatment options (RP: 5; RT: 9; RP ± RT: 7; metastasis-directed therapy: 28) with (72%) or without (28%) systemic treatment. The remaining two are imaging studies. Progression-free (PFS; 17/41; 41%) or overall survival (OS; 3/41; 7%) is defined as primary endpoint in half of all trials, others are 'safety/toxicity' or 'PSA response'. Conclusions: With 41 ongoing trials, there is great interest in oligometastatic PCa. Most trials address local ablative treatments both for prostate and/or metastases, typically by radiotherapy, and several attempts to determine the benefit of adding systemic therapy. The field will hopefully have definitive answers after completion of four ongoing phase III trials. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

230. Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment

Author

Sharabi, Andrew B., Tran, Phuoc T., Lim, Michael, Drake, Charles G., and Deweese, Theodore L.

Subjects
Oncology, Experimental, Immunotherapy -- Methods, Radiotherapy -- Methods, Cancer -- Research, Health
Abstract

Stereotactic radiosurgery and stereotactic body radiation therapy are two contemporary radiation modalities that can treat tumors in any area of the body using highly focused radiation. Recently, immunotherapy has established itself as a viable and powerful anticancer treatment. In this review we detail the rationale supporting a combination of immunotherapy and stereotactic radiation. Additionally, we discuss the evidence for the immune stimulatory effects of focused radiation and the role that radiation may play in enhancing the systemic treatment effects of immunotherapy., Introduction Radiation therapy has a long and established history in the field of oncology. [1] The term stereotactic radiation--or stereotaxy--refers to the use of a referenced three-dimensional coordinate system to [...]

Published
2015

231. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer

Author

Deek, Matthew P., Taparra, Kekoa, Phillips, Ryan, Velho, Pedro Isaacsson, Gao, Robert W., Deville, Curtiland, Song, Daniel Y., Greco, Stephen, Carducci, Michael, Eisenberger, Mario, DeWeese, Theodore L., Denmeade, Samuel, Pienta, Kenneth, Paller, Channing J., Antonarakis, Emmanuel S., Olivier, Kenneth R., Park, Sean S., Tran, Phuoc T., and Stish, Bradley J.

Abstract

Available therapies for castrate-resistant prostate cancer (CRPC) confer minimal survival advantage; thus, there is interest in metastasis-directed therapy (MDT) for oligometastatic or oligoprogressive disease to improve outcomes. Here, we describe outcomes of oligoprogressive CRPC treated with stereotactic ablative radiotherapy (SABR).

Published
2021
Full Text
View/download PDF

232. Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712

Author

Rana, Zaker, Kamran, Sophia C., Shetty, Amol C., Sutera, Philip, Song, Yang, Bazyar, Soha, Solanki, Abhishek A., Simko, Jeffry P., Pollack, Alan, McConkey, David, Kates, Max, Siddiqui, M. Minhaj, Hiken, Jeffrey, Earls, Jon, Messina, David, Mouw, Kent W., Miyamoto, David, Shipley, William U., Michaelson, M. Dror, Zietman, Anthony, Coen, John J., Dahl, Douglas M., Jani, Ashesh B., Souhami, Luis, Chang, Brian K., Lee, R. Jeffrey, Pham, Huong, Marshall, David T., Shen, Xinglei, Pugh, Stephanie L., Feng, Felix Y., Efstathiou, Jason A., Tran, Phuoc T., and Deek, Matthew P.

Abstract

A novel transcriptional profiling platform revealed that gene expression consistent with high immune-cell infiltration and of specific genes associated with T-cell infiltration or IFNγ signaling was correlated with better survival following chemoradiation for muscle-invasive bladder cancer.

Published
2024
Full Text
View/download PDF

233. External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial

Author

Ross, Ashley E., Zhang, Jingbin, Huang, Huei-Chung, Yamashita, Rikiya, Keim-Malpass, Jessica, Simko, Jeffry P., DeVries, Sandy, Morgan, Todd M., Souhami, Luis, Dobelbower, Michael C., McGinnis, L. Scott, Jones, Christopher U., Dess, Robert T., Zeitzer, Kenneth L., Choi, Kwang, Hartford, Alan C., Michalski, Jeff M., Raben, Adam, Gomella, Leonard G., Sartor, A. Oliver, Rosenthal, Seth A., Sandler, Howard M., Spratt, Daniel E., Pugh, Stephanie L., Mohamad, Osama, Esteva, Andre, Chen, Emmalyn, Schaeffer, Edward M., Tran, Phuoc T., and Feng, Felix Y.

Abstract

Multimodal artificial intelligence models using digital histopathology slides outperform clinical and pathological variables for prognostic prediction of distant metastasis and prostate cancer–specific mortality, and can be incorporated in clinical practice for personalized risk stratification.

Published
2024
Full Text
View/download PDF

234. Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer

Author

Sutera, Philip, Song, Yang, Shetty, Amol C., English, Keara, Van der Eecken, Kim, Guler, Ozan Cem, Wang, Jarey, Cao, Yufeng, Bazyar, Soha, Verbeke, Sofie, Van Dorpe, Jo, Fonteyne, Valérie, De Laere, Bram, Mishra, Mark, Rana, Zaker, Molitoris, Jason, Ferris, Matthew, Kiess, Ana, Song, Daniel Y., DeWeese, Theodore, Pienta, Kenneth J., Barbieri, Christopher, Marchionni, Luigi, Ren, Lei, Sawant, Amit, Simone, Nicole, Berlin, Alejandro, Onal, Cem, Tran, Phuoc T., Ost, Piet, and Deek, Matthew P.

Abstract

For patients with metachronous oligometastatic castration-sensitive prostate cancer, tumor genomics may play a role in the mode of progression and pattern of failure after initial therapy for metastatic disease. Specifically, patients with TP53and RB1mutations have a higher likelihood of progression, and TP53, SPOP, and WNT pathway mutations may have a role in metastatic organotropism directing the likelihood of bone and visceral disease progression.

Published
2024
Full Text
View/download PDF

235. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer

Author

Deek, Matthew P., Sutera, Philip, Jing, Yuezhou, Gao, Robert, Rothman, Emily, Day, Heather, Chang, David, Dirix, Piet, Armstrong, Andrew J., Campbell, Bethany, Lopez Campos, Fernando, Berenguer, Miguel, Ramotar, Matthew, Conde-Moreno, Antonio, Berlin, Alejandro, Giovanni Bosetti, Davide, Corcoran, Niall, Koontz, Bridget, Mercier, Carole, Siva, Shankar, Pryor, David, Ost, Piet, Anh Huynh, Mai, Kroeze, Stephanie, Stish, Bradley, Kiess, Ana, Trock, Bruce, Tran, Phuoc T., Gillessen, Silke, and Sweeney, Christopher

Abstract

The optimal integration of metastasis-directed therapy (MDT) is not known. In this large multi-institutional report, the addition of concurrent androgen deprivation therapy to MDT appears to improve outcomes, although about 10% patients had durable control with MDT alone.

Published
2024
Full Text
View/download PDF

237. Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer.

Author

Deek, Matthew P. and Tran, Phuoc T.

Abstract

Our understanding of metastatic disease is rapidly advancing, with recent evidence supporting an oligometastatic state currently defined by patients having a limited (typically ≤5) number of metastatic deposits. The optimal management of these patients is also shifting toward increased integration of local therapies, with emerging evidence suggesting metastasis-directed therapy can improve overall survival. Additionally, the use of stereotactic ablative radiation therapy within castration-sensitive oligometastatic prostate cancer cohorts appears to forestall the need to initiate systemic therapy, which has unfavorable side effect profiles, such as androgen deprivation therapy, while itself being associated with little toxicity. We review the literature surrounding the use of metastasis-directed therapy in the treatment of oligometastatic prostate cancer by reviewing the evidence for its use within 3 subgroups: de novo synchronous, oligorecurrent, and oligoprogressive disease. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

238. Radiotherapy in the Management of Metastatic Hormone-Sensitive Prostate Cancer: What Is the Standard of Care?

Author

Deek, Matthew P., Phillips, Ryan, and Tran, Phuoc T.

Abstract

Systemic therapy has historically been the backbone of treatment for patients with metastatic disease. However, recent evidence suggests metastasis-directed therapy in those with oligometastatic disease (≤5 lesions) may improve progression-free and overall survival. Within prostate cancer-specific cohorts, metastasis-directed therapy also appears to delay the time to initiation of androgen deprivation therapy while also generally being associated with a mild toxicity profile and has thus garnered interest as a means to delay systemic therapy. Here we review the evidence surrounding the use of radiation therapy to metastatic sites in patients with metastatic hormone-sensitive prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

239. Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

Author

Moyer, C. Leigh, Phillips, Ryan, Deek, Matthew P., Radwan, Noura, Ross, Ashley E., Antonarakis, Emmanuel S., Reyes, Diane, Wright, Jean, Terezakis, Stephanie A., Song, Daniel Y., DeVille, Curtiland, Walsh, Patrick C., DeWeese, Theodore L., Carducci, Michael, Schaeffer, Edward M., Pienta, Kenneth J., Eisenberger, Mario, and Tran, Phuoc T.

Subjects
PROSTATE cancer, RADIOTHERAPY, PROGRESSION-free survival, PROSTATE-specific antigen, BONE metastasis
Abstract

Purpose: Local ablative treatment to oligometastatic patients can result in long-term disease-free survival in some cancer patients. The importance of this treatment paradigm in prostate cancer is a rapidly evolving field. Herein, we report on the safety and preliminary clinical outcomes of a modern cohort of oligometastatic prostate cancer (OPC) patients treated with consolidative stereotactic ablative radiation (SABR). Methods: Records of men with OPC who underwent consolidative SABR at our institution were reviewed. SABR was delivered in 1–5 fractions of 5–18 Gray. Kaplan–Meier estimates of local progression-free survival (LPFS), biochemical progression-free survival (bPFS; PSA nadir + 2), distant progression-free survival (DPFS), and time-to-next intervention (TTNI) were calculated. Results: In total, 66 OPC patients were identified with consolidative SABR delivered to 134 metastases: 89 bone, 40 nodal, and 5 viscera. The majority of men (49/66) had hormone-sensitive prostate cancer (HSPC). Crude grade 1 and 2 acute toxicities were 36% and 11%, respectively, with no ≥ grade 3 toxicity. At 1 year, LPFS was 92% and bPFS and DPFS were 69%. Of the 18 men with HSPC who had deferred hormone therapy , 11 (56%) remain disease free following SABR (1-year ADT-FS was 78%). In 17 castration-resistant men, 11 had > 50% prostate-specific antigen (PSA) declines with 1-year TTNI of 30%. Conclusions: Consolidative SABR in OPC is feasible and well tolerated. The heterogeneity and small size of our series limit extrapolation of clinically meaningful outcomes following consolidative SABR in OPC, but our preliminary data suggest that this approach warrants continued prospective study. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

240. Metastasis-Directed Therapy In Prostate Cancer: Why, When, and How?

Author

Phillips, Ryan M., Deek, Matthew P., DeWeese, Theodore L., and Tran, Phuoc T.

Abstract

Metastatic prostate cancer remains a life-limiting disease; while we have seen significant advances in systemic approaches which form the backbone of management, no curative paradigm yet exists. Metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy (SABR) has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer. Herein we will review the rationale, potential benefits, and practical considerations associated with this approach. [ABSTRACT FROM AUTHOR]

Published
2019

241. O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis

Author

Taparra, Kekoa, primary, Wang, Hailun, additional, Malek, Reem, additional, Lafargue, Audrey, additional, Barbhuiya, Mustafa A., additional, Wang, Xing, additional, Simons, Brian W., additional, Ballew, Matthew, additional, Nugent, Katriana, additional, Groves, Jennifer, additional, Williams, Russell D., additional, Shiraishi, Takumi, additional, Verdone, James, additional, Yildirir, Gokben, additional, Henry, Roger, additional, Zhang, Bin, additional, Wong, John, additional, Wang, Ken Kang-Hsin, additional, Nelkin, Barry D., additional, Pienta, Kenneth J., additional, Felsher, Dean, additional, Zachara, Natasha E., additional, and Tran, Phuoc T., additional

Published
2018
Full Text
View/download PDF

242. Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment

Author

Moyer, C. Leigh, primary, Phillips, Ryan, additional, Deek, Matthew P., additional, Radwan, Noura, additional, Ross, Ashley E., additional, Antonarakis, Emmanuel S., additional, Reyes, Diane, additional, Wright, Jean, additional, Terezakis, Stephanie A., additional, Song, Daniel Y., additional, DeVille, Curtiland, additional, Walsh, Patrick C., additional, DeWeese, Theodore L., additional, Carducci, Michael, additional, Schaeffer, Edward M., additional, Pienta, Kenneth J., additional, Eisenberger, Mario, additional, and Tran, Phuoc T., additional

Published
2018
Full Text
View/download PDF

243. Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system

Author

Maxwell, Russell, primary, Luksik, Andrew S., additional, Garzon-Muvdi, Tomas, additional, Hung, Alice L., additional, Kim, Eileen S., additional, Wu, Adela, additional, Xia, Yuanxuan, additional, Belcaid, Zineb, additional, Gorelick, Noah, additional, Choi, John, additional, Theodros, Debebe, additional, Jackson, Christopher M., additional, Mathios, Dimitrios, additional, Ye, Xiaobu, additional, Tran, Phuoc T., additional, Redmond, Kristin J., additional, Brem, Henry, additional, Pardoll, Drew M., additional, Kleinberg, Lawrence R., additional, and Lim, Michael, additional

Published
2018
Full Text
View/download PDF

244. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer

Author

Yochum, Zachary A., primary, Cades, Jessica, additional, Wang, Hailun, additional, Chatterjee, Suman, additional, Simons, Brian W., additional, O’Brien, James P., additional, Khetarpal, Susheel K., additional, Lemtiri-Chlieh, Ghali, additional, Myers, Kayla V., additional, Huang, Eric H.-B., additional, Rudin, Charles M., additional, Tran, Phuoc T., additional, and Burns, Timothy F., additional

Published
2018
Full Text
View/download PDF

245. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation

Author

Vendetti, Frank P., primary, Karukonda, Pooja, additional, Clump, David A., additional, Teo, Troy, additional, Lalonde, Ronald, additional, Nugent, Katriana, additional, Ballew, Matthew, additional, Kiesel, Brian F., additional, Beumer, Jan H., additional, Sarkar, Saumendra N., additional, Conrads, Thomas P., additional, O’Connor, Mark J., additional, Ferris, Robert L., additional, Tran, Phuoc T., additional, Delgoffe, Greg M., additional, and Bakkenist, Christopher J., additional

Published
2018
Full Text
View/download PDF

248. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study

Author

Sandler, Kiri A., primary, Cook, Ryan R., additional, Ciezki, Jay P., additional, Ross, Ashley E., additional, Pomerantz, Mark M., additional, Nguyen, Paul L., additional, Shaikh, Talha, additional, Tran, Phuoc T., additional, Stock, Richard G., additional, Merrick, Gregory S., additional, Demanes, D. Jeffrey, additional, Spratt, Daniel E., additional, Abu-Isa, Eyad I., additional, Wedde, Trude B., additional, Lilleby, Wolfgang, additional, Krauss, Daniel J., additional, Shaw, Grace K., additional, Alam, Ridwan, additional, Reddy, Chandana A., additional, Song, Daniel Y., additional, Klein, Eric A., additional, Stephenson, Andrew J., additional, Tosoian, Jeffrey J., additional, Hegde, John V., additional, Yoo, Sun Mi, additional, Fiano, Ryan, additional, D'Amico, Anthony V., additional, Nickols, Nicholas G., additional, Aronson, William J., additional, Sadeghi, Ahmad, additional, Greco, Stephen C., additional, Deville, Curtiland, additional, McNutt, Todd, additional, DeWeese, Theodore L., additional, Reiter, Robert E., additional, Said, Jonathan W., additional, Steinberg, Michael L., additional, Horwitz, Eric M., additional, Kupelian, Patrick A., additional, King, Christopher R., additional, and Kishan, Amar U., additional

Published
2018
Full Text
View/download PDF

249. Abstract 1094: A role for olfactory-like chemosensory signaling in prostate cancer metastasis

Author

Lam, Hong, primary, Zhu, Wanqu, additional, Wang, Hailun, additional, Luo, Jun, additional, Zheng, Qizhi, additional, Valkenburg, Ken, additional, Hurley, Paula, additional, Pluznick, Jennifer L., additional, Tran, Phuoc T., additional, Marzo, Angelo M. De, additional, Isaacs, William B., additional, Pienta, Kenneth J., additional, and An, Steven S., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results